Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.29 EUR
Change Today -0.009 / -3.03%
Volume 1.3M
PHARM On Other Exchanges
EN Amsterdam
As of 4:35 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

pharming group nv (PHARM) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/2/14 - €0.46
52 Week Low
08/24/15 - €0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PHARMING GROUP NV (PHARM)

Related News

No related news articles were found.

pharming group nv (PHARM) Related Businessweek News

No Related Businessweek News Found

pharming group nv (PHARM) Details

Pharming Group N.V. develops, produces, and commercializes human therapeutic proteins for unmet medical needs. It is involved in the production, purification, formulation, and development of recombinant protein products. The company offers Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor (rhC1INH) for ischemia-reperfusion injury (IRI) indications, including myocardial infarction, stroke, and delayed graft function in transplantation; and rhFactor VIII for Haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

53.8 Employees
Last Reported Date: 03/18/15

pharming group nv (PHARM) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €624.0K
Chief Operations Officer and Member of Manage...
Total Annual Compensation: €391.0K
Compensation as of Fiscal Year 2014.

pharming group nv (PHARM) Key Developments

Pharming Group NV Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015

Pharming Group NV reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported revenues of EUR 5,235,000 compared to EUR 2,539,000 a year ago. Operating loss was EUR 6,062,000 against EUR 5,418,000 a year ago. Loss before income tax was EUR 3,487,000 compared to EUR 17,688,000 a year ago. Net loss from continuing operations was EUR 3,487,000 compared to EUR 17,688,000 a year ago. Net loss from continuing operations attributable to the owners of the parent was EUR 3,487,000 or EUR 0.009 per basic share compared to EUR 17,688,000 or EUR 0.047 per basic share. Net cash flows used in operating activities EUR 8,698,000 compared to EUR 11,010,000 a year ago. Purchase of property, plant and equipment was EUR 476,000. Revenues were increased mainly as a result of product sales in the US.

Pharming Group NV, H1 2015 Earnings Call, Jul 30, 2015

Pharming Group NV, H1 2015 Earnings Call, Jul 30, 2015

Pharming Group NV Enters into Straight Debt Financing of EUR 15.6 Million

Pharming Group NV announced that it has entered into a straight debt financing of EUR 15.6 million (EUR 15.0 million net proceeds after subtraction of transaction fees and costs) with Oxford Finance LLC and Silicon Valley Bank. Under the terms and conditions of the agreement, the lenders provide USD 17 million secured senior debt funding against 48 months promissory notes with a 7.02% fixed interest per annum. The initial 12 months of the notes are interest only, followed by monthly re-payment of the notes in a 36 months straight amortization scheme. As further consideration for the facility, the lenders will receive a 3.95% warrant coverage (2,124,328 warrants) with a strike price of EUR 0.29, representing the average closing price of Pharming shares over the last ten days prior to the closing date and a final payment on maturation (1 July 2019) of 9% of the principal sum.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHARM:NA €0.29 EUR -0.009

PHARM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €12.34 EUR -0.26
BioCryst Pharmaceuticals Inc $11.64 USD +0.22
Oxford Biomedica PLC 7.66 GBp -0.49
Shire PLC 4,841 GBp -184.00
View Industry Companies

Industry Analysis


Industry Average

Valuation PHARM Industry Range
Price/Earnings 14.6x
Price/Sales 4.3x
Price/Book 4.5x
Price/Cash Flow 14.9x
TEV/Sales 4.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMING GROUP NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at